Business
Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ
NEW YORK, June 7, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, June 7, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ, a novel therapeutic for the treatment of symptoms related to Alzheimer's disease. \n\n \n \n \n \n \n \n\n \nThe research will be led by Carla Yuede, PhD, Associate Professor of Psychiatry, and John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine. Dr. Cirrito's research has been focused on the relationship between synaptic activity and amyloid-beta metabolism in Alzheimer's disease. Amyloid-beta (Abeta) peptide accumulation within the brain extracellular space, as toxic oligomers and plaques, is strongly believed to be the primary cause of Alzheimer's disease. Dr. Yuede's research is primarily focused on the factors influencing cognitive function and brain Aß dynamics in mouse models of Alzheimer's Disease, particularly in relation to synaptic activity.\n\"We are pleased to expand our work in the Alzheimer's disease space through our partnership with Dr. John Cirrito, Dr. Carla Yuede, and Washington University,\" said Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc. \"Our focus remains on bringing innovative and novel therapeutics through development to address unmet patient needs and drive shareholder value, and we are excited about the potential impact of HT-ALZ on the treatment of Alzheimer's disease and all of those affected by it.\"\n\"The collaboration with Hoth Therapeutics is designed to explore a novel route toward the treatment of symptoms of Alzheimer's disease in pre-clinical models,\" said Yuede. \"We are excited about the potential for new understanding in this area.\" \nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements ...